Bioprocessing of Viral Vectors and Vaccines

主席在上一个任期内取得的主要成就包括：-将流感种子储备的产生从数月加速到数周，以便利用细胞培养技术和逆向工程快速生产疫苗，以应对大流行情况。埃塞俄比亚纽卡斯尔病腺病毒载体疫苗生产工艺的开发和技术转让，以保护牲畜。 - 在悬浮液和无血清培养基中操作的Vero细胞系生产平台的先进工艺开发，用于生产针对埃博拉病毒，HIV和SARS-CoV-2候选疫苗的重组水泡性口炎病毒载体疫苗。在加拿大和国外开展能力建设和高素质人员（HQP）培训，以支持应对新出现和重新出现的传染病的准备计划。在这些具有影响力的成就的基础上，目前业界正在利用这些成就加速开发针对COVID-19大流行的载体疫苗，拟议的CRC Tier 1研究计划在生物过程科学和病毒载体和疫苗技术的重点是复杂的生物系统和细胞动力学的逆向工程。病毒的相互作用，以设计先进的制造工艺，安全，有效和具有成本效益的疫苗和体内基因编辑的输送系统。一种系统方法，整合1）病毒和细胞生物平台的基因组规模重新设计，2）持续的过程加速和强化，3）过程分析技术和数据科学，以支持高价值药物的交付，以应对新出现和重新出现的传染病。该研究计划建立在与工业和机构合作伙伴的长期合作基础上，以支持新技术的转化，并支持高价值病毒产品的商业化。该计划还旨在为HQP提供坚实的培训，以满足加拿大生物制造业的需求，并在先进疫苗制造的战略领域建立持续的能力。

The major accomplishments achieved by the chair during the previous term include: - Acceleration of influenza seed stocks generation from months to weeks to enable rapid vaccine manufacturing in response to pandemic situations using cell culture technology and reverse engineering.- Development and technology transfer of manufacturing process for adenovirus-vectored vaccine against Newcastle Disease infection for protection of livestock in Ethiopia. - Advanced process development of a Vero cell line production platform operated in suspension and serum free media for manufacturing of recombinant Vesicular Stomatitis Virus-vectored vaccine against Ebola, HIV and SARS-CoV-2 candidate vaccines.- Capacity building and Highly Qualified Perosonnel (HQP) training in Canada and abroad to support preparedness plans in response to emerging and re-emerging infectious diseases.Building on these impactful achievements, that are currently used by industry for accelerated development of vectored vaccines against COVID-19 pandemic, the proposed CRC Tier 1 research program in Bioprocess Sciences and Technology of Viral Vectors and Vaccines focuses on reverse engineering of complex biological systems and dynamics of cell/virus interaction to design advanced manufacturing processes for safe, efficacious and cost-effective vaccines and delivery systems for in-vivo gene editing. A system approach integrating 1) genome-scale re-design of viral and cellular biological platforms, 2) continuous process acceleration and intensification, 3) process analytical technologies and data sciences, to support the delivery of high-value medicines in response to emerging and re-emerging infectious diseases. The research program builds on long-lasting collaborations with industrial and institutional partners to support translation of novel technologies and support commercialization of high value viral-based products. The program is also designed to provide solid training for HQPs to meet the needs of the Canadian biomanufacturing industry and build sustained capacity in the strategic area of advanced vaccine manufacturing.